Al-Zoubi Mohammad, Alarabiyat Moath, Hann Angus, Mehrzhad Homoyon, Karkhanis Salil, Muiesan Paolo, Abradelo Manuel, Hartog Hermien, Roberts Keith, Mirza Darius F, Isaac John R, Dasari Bobby V M
Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom.
Department of General Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Transplant Direct. 2022 Jul 19;8(8):e1350. doi: 10.1097/TXD.0000000000001350. eCollection 2022 Aug.
Persistent ascites after orthotropic liver transplantation has numerous causes and can be challenging to manage. This study aimed to determine the outcomes associated with conservative and endovascular intervention of posttransplant ascites after deceased donor liver transplantation.
Adult (≥18 y) liver transplant recipients (between 2006 and 2019) who underwent hepatic venous pressure studies to investigate posttransplant ascites were included in this retrospective study. Comparisons were made between those who were managed with conservative therapy versus endovascular intervention and were also based on hepatic venous wedge pressure gradient (normal [≤10 mm Hg] versus elevated [>10 mm Hg]).
A total of 30 patients underwent hepatic venography to investigate ascites during the study period. The median time from transplant to venography was 70 d. At least 1 endovascular intervention was performed in 18 of 30 patients (62%), and 12 of 30 patients (38%) were managed conservatively. Endovascular interventions included angioplasty (n = 4), hepatic vein stenting (n = 9), or a transjugular intrahepatic portosystemic shunt (n = 7). The mean (range) hepatic venous wedge pressure gradient for the conservative and endovascular intervention groups was 12 mm Hg (3-23) and14 mm Hg (2-35), respectively. At a 6-mo follow-up, ascites resolved in 6 of 12 patients (50%) and 11 of 18 patients (61%) in the medical management and endovascular groups, respectively. The graft survival rates at 6 and 12 mo were (7/12 [58%] versus 17/18 [94%], = 0.02) and (7/12 [58%] versus 14/18 [78%], = 0.25), respectively.
Despite medical or endovascular intervention, resolution of ascites is achieved in <60% of patients with persistent ascites. Biopsy findings and venographic pressure studies should be carefully integrated into the management of posttransplant ascites.
原位肝移植后持续性腹水有多种原因,管理起来可能具有挑战性。本研究旨在确定在已故供体肝移植后,对移植后腹水进行保守治疗和血管内介入治疗的相关结果。
本回顾性研究纳入了2006年至2019年间接受肝静脉压力研究以调查移植后腹水的成年(≥18岁)肝移植受者。对接受保守治疗与血管内介入治疗的患者进行了比较,并且还基于肝静脉楔压梯度(正常[≤10mmHg]与升高[>10mmHg])进行比较。
在研究期间,共有30例患者接受了肝静脉造影以调查腹水。从移植到静脉造影的中位时间为70天。30例患者中有18例(62%)至少进行了1次血管内介入治疗,30例患者中有12例(38%)接受了保守治疗。血管内介入治疗包括血管成形术(n = 4)、肝静脉支架置入术(n = 9)或经颈静脉肝内门体分流术(n = 7)。保守治疗组和血管内介入治疗组的平均(范围)肝静脉楔压梯度分别为12mmHg(3 - 23)和14mmHg(2 - 35)。在6个月的随访中,药物治疗组和血管内介入治疗组分别有12例患者中的6例(50%)和18例患者中的11例(61%)腹水消退。6个月和12个月时的移植物存活率分别为(7/12 [58%]对17/18 [94%],P = 0.02)和(7/12 [58%]对14/18 [78%],P = 0.25)。
尽管进行了药物或血管内介入治疗,但持续性腹水患者中腹水消退的比例不到60%。活检结果和静脉造影压力研究应仔细纳入移植后腹水的管理中。